DB-101

DB-101 is an investigational gene therapy consisting of a replication-deficient recombinant adenovirus (type 5) vector that encodes the human interferon-gamma (hIFN-γ) gene. Developed by Guangzhou Dabo Biological Products, it is primarily targeted at treating metastatic castration-resistant prostate cancer (mCRPC). Upon administration, the viral vector transduces host cells, leading to the localized expression and secretion of IFN-γ. This cytokine plays a critical role in activating the immune system by enhancing the activity of natural killer (NK) cells and cytotoxic T lymphocytes, increasing MHC class I and II expression, and exerting direct anti-proliferative and pro-apoptotic effects on tumor cells. The localized delivery aims to maximize therapeutic efficacy while minimizing the systemic toxicity typically associated with recombinant IFN-γ protein administration.

Other names

adenoviral vector encoding human interferon-gammaAd-hIFN-gammarecombinant human interferon-gamma adenovirus injection